Synthetic, 20 base phosphorothioate antisense oligonucleotide designed to inhibit protein kinase C-α (PKC-α) expression. Prepn: C. F. Bennett, N. Dean, WO 9319203; eidem, US 5882927 (1993, 1999 both to Isis). Pharmacology: N. Dean et al., Cancer Res. 56, 3499 (1996). CGE determn in tissue: R. S. Geary et al., Anal. Biochem. 274, 241 (1999). Clinical pharmacology and evaluation in advanced cancer: J. Nemunaitis et al., J. Clin. Oncol. 17, 3586 (1999). Review of pharmacokinetics: P. L. Nicklin et al., Handb. Exp. Pharmacol. 131, 141-168 (1998). Review of development and clinical evaluations: J. T. Holmlund et al., Curr. Opin. Mol. Ther. 3, 372-385 (1999); K. Li, J. Zhang, Curr. Opin. Investig. Drugs 2, 1454-1461 (2001).
Antineoplastic.
Antineoplastic; Oligonucleotides